Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL651892 | 0.88 | HDAC1 (0.71) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL653692 | 0.85 | HDAC1 (0.50) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL3692595 | 0.84 | HDAC1 (0.54) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL23673781 | 0.84 | HDAC1 (0.74) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL654755 | 0.81 | HDAC1 (0.60) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL4313201 | 0.80 | HDAC2 (0.50) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL4320582 | 0.78 | HDAC1 (0.51) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL4318022 | 0.78 | HDAC1 (0.58) | HDAC1HDAC2HDAC3 | |
| SCHEMBL4669167 | 0.77 | HDAC1 (0.59) | HDAC1HDAC2HDAC3 | |
| SCHEMBL1066546 | 0.76 | HDAC1 (0.60) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013196-B1 | DISUBSTITUTED ANILINE COMPOUNDS | MERCK SHARP & DOHME (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20090221669-A1 | Disubstituted Aniline Compounds | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | disclosed |
| EP-2013196-A2 | DISUBSTITUTED ANILINE COMPOUNDS | Merck & Co., Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007127137-A2 | DISUBSTITUTED ANILINE COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221669-A1 | Disubstituted Aniline Compounds | TXNRD2, BRDT, HDAC1 | HDAC1 3/4885HDAC2 14/4885HDAC3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.